<html>
<body>
<table style="margin: 0px; padding: 0px; width: 100%;" bgcolor="#e3dbc7">
<tbody>
<tr>
<td>
<div style="padding: 30px; margin: 0px;">
<table align="center" cellpadding="0" cellspacing="0" bgcolor="#eee9db"
style="font-family: Verdana; border: 1px solid #f3f0e7; width: 600px;">
<tbody>
<tr>
<td style="padding: 15px 15px 0px 15px;">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%;">
<tbody>
<tr>
<td align="center" valign="top" style="padding: 0px 20px 15px 20px; color:
#993300;">
<p align="center" style="font-family: 'Georgia'; font-weight: normal;
letter-spacing: 0px; color: #663300; font-size: 40px; line-height: 40px;
padding: 5px 0px; margin: 0px;">Nuvilex Inc. (NVLX)</p>
</td>
</tr>
<tr>
<td align="center" valign="top" bgcolor="#ffb600" style="padding: 15px
20px;">
<p style="font-size: 15px; font-family: 'Georgia'; color: #663300; padding:
5px 0px; margin: 0px;"><strong><strong><b>Nuvilex Partnership with Medical
Tital Is a Significant Victory for Shareholders</b></strong></strong></p>
</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td style="padding: 0px 15px;">
<table border="0" cellpadding="0" cellspacing="20" bgcolor="#ffffff"
style="width: 100%;">
<tbody>
<tr>
<td valign="top" style="padding: 0px;" align="center">
<p align="justify" style="font-size: 11px; line-height: 1.3em; font-family:
'Verdana'; color: #5f5a50;"><span>Nuvilex, Inc. (OTCQB – NVLX) just
announced they have entered into a agreement with Fisher BioServices, Inc.,
a subsidy of medical services behemoth Thermo Fisher Scientific, Inc. (NYSE
– TMO), for the long-term storing of cells that will be necessary for
future Phase III clinical trials in pancreatic cancer and for studies in
other cancers as well. This is a huge deal for Nuvilex and reveals how far
along the Firm is in clinical trial development, which should take the
stock’s valuation notably higher. Fisher BioServices is one of the
prominent organizations in critical biological material management and cell
and tissue storage with locations world-wide and its $30B in market cap
parent employs 39,000 world-wide. Fisher BioServices has stowed more than
170M biospecimens, including cells and tissues, as well as their related
information. Notably, their facilities are fully GMP amenable –
a requirement for an NDA filing.<br /><br />The Fisher BioServices
location, located in Rockville, MD, is just a few miles from
Nuvilex’s International Headquarters, and will be used as one of many
cell storage sites world-wide retaining the cells to be encapsulated that
are part of Nuvilex’s pancreatic cancer treatment.<br /><br />Goldman
Small Cap Research notes in a new release (<a
href="http://service.hotspotbirmanoho.net/link.php?M=6588707&N=4246&L=23&F=H"><font color="red"><b>MailScanner has detected a possible fraud attempt from "service.hotspotbirmanoho.net" claiming to be</b></font> www.goldmanresearch.com</a></span><span><span>)
that this partnership is a critical step for Nuvilex and verifies the
Organization’s rank as a well-respected player in the cancer
treatment development segment. Moreover, Goldman states that by entering
into a partnership with the industry leader, Nuvilex is setting an example
to the industry and their shareholders that the Company is devoted to
reaching its clinical trials and FDA approval objectives as quickly as
possible.</span><br /><br /></span><span>260 Madison Avenue, Eighth Floor,
NY, NY 10016</span></p>
</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table border="0" cellspacing="0" cellpadding="0" style="padding: 5px 30px;
color: #aea48b; font-size: 10px; width: 100%;">
<tbody>
<tr>
<td width="100%">
<p align="justify" style="font-size: 10px; line-height: 1.5em; font-family:
'Verdana'; color: #000;">The use of research materials circulated by the
auth.or is done at your own risk. You are encouraged to do your own
research before making any investment decision in regards to the secu rity
discussed herein. The author has not been rewarded by any entity in
connection with the distribution of these materials. You should presume
that as of the date of this report or letter, the author, possibly along
with or through our owners, affiliates, employees and/or consultants,
(cooperatively referred to as the author) has a position in all company
shares (and/or options of the shares) covered herein that is consistent
with the position set forth in our report. In connection with NVLX, the
author has taken a long position. Following the disbursement of any report
or letter, the author intends to continue engaging in trnsactns in the secu
rity covered herein, and we may be long, short, and/or neutral at any time
hereafter regardless of our initial position and we preserve the right to
procure or trade all or part of our position at any time without notice.
This practice could end in our trading securities at any time before,
during, and/or after the disbursement of this report.</p>
<p align="center"><a
href="http://service.hotspotbirmanoho.net/unsubscribe.php?M=6588707&C=0a89a74737fe0ab850bde605efc11be4&L=54&N=4246">Discontinue
me from this newsletter</a></p>
</td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
</td>
</tr>
</tbody>
</table>
<img
src="http://service.hotspotbirmanoho.net/open.php?M=6588707&L=54&N=4246&F=H&image=.jpg"
height="1" width="10"></body>
</html>